Prostaglandin E1 in Outpatients With Intermittent Claudication

Intermittent Claudication Fontaine Stage II PAOD Clinical Trial

Official title: Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication

Status Completed

Clinical Trial Summary

Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with Intermittent Claudication.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arterial Occlusive Diseases
• Intermittent Claudication
• Intermittent Claudication Fontaine Stage II PAOD
• Peripheral Arterial Disease
• Stage II Peripheral Arterial Occlusive Disease

• NCT number: NCT01263925
• Study type: Interventional
• Source: UCB Pharma
• Status: Completed
• Phase: Phase 3
• Start date: April 2001
• Completion date: April 2011